Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients
Launched by HASSELT UNIVERSITY · May 12, 2015
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast adenocarcinoma
- • Treatment with primary breast-sparing surgery (lumpectomy) and/or neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy or hormonal therapy
- • Scheduled for postoperative radiotherapy with standard technique (isocentric) and fractionation regime (i.e. 25 daily fractions of 2 Gray to the whole breast followed by a boost of 8 fractions of 2 Gray to the tumor bed, 5/week)
- • Signed informed consent
- Exclusion Criteria:
- • Previous irradiation to the same breast
- • Metastatic disease
- • Concurrent chemotherapy
- • Required use of bolus material to deliver radiotherapy (i.e. material placed on the to- be-irradiated zone to modulate the delivered dose in order the ensure an optimal distribution of the radiation dose; mostly used for treatment of superficial tumors)
About Hasselt University
Hasselt University is a prestigious research institution located in Belgium, renowned for its commitment to advancing scientific knowledge and innovation. With a strong focus on interdisciplinary research, the university actively engages in clinical trials that aim to address pressing health challenges. Leveraging a robust network of collaborations with healthcare professionals, industry partners, and research organizations, Hasselt University strives to translate research findings into practical applications that benefit patient care and public health. The institution is dedicated to maintaining the highest ethical standards and regulatory compliance in all its clinical research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hasselt, , Belgium
Patients applied
Trial Officials
Jeroen Mebis, prof. dr.
Principal Investigator
Universiteit Hasselt/ Jessa ziekenhuis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials